RenovoRx, Inc. (RNXT)
| Market Cap | 50.51M +21.2% |
| Revenue (ttm) | 1.49M +520.4% |
| Net Income | -12.27M |
| EPS | -0.33 |
| Shares Out | 45.10M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 425,287 |
| Open | 1.140 |
| Previous Close | 1.150 |
| Day's Range | 1.100 - 1.160 |
| 52-Week Range | 0.701 - 1.450 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 7.03 (+527.68%) |
| Earnings Date | Aug 12, 2026 |
About RNXT
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Financial Performance
In 2025, RenovoRx's revenue was $1.12 million, an increase of 2511.63% compared to the previous year's $43,000. Losses were -$11.17 million, 26.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for RNXT stock is "Strong Buy." The 12-month stock price target is $7.03, which is an increase of 527.68% from the latest price.
News
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M First Treatment Delivered with RenovoCath ® in Patient with Sarcoma in Clinical Setting, Marking Expansion of Device to Other Sol...
RenovoRx completes enrollment in TIGeR-PaC trial
RenovoRx (RNXT) announced completion of enrollment in the company’s Phase III TIGeR-PaC trial in locally advanced pancreatic cancer. As of August 7, TIGeR-PaC trial investigators have been notified by...
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
MOUNTAIN VIEW, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and comm...
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors
MOUNTAIN VIEW, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and comm...
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th
MOUNTAIN VIEW, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and comm...
RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET
MOUNTAIN VIEW, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and comm...
RenovoRx Transcript: IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026
The presentation highlighted a targeted, high-margin commercial strategy for a novel cancer therapy device, with rapid adoption in top centers, strong interim clinical data showing improved survival and reduced toxicity, and expansion into new indications. Break-even is expected next year, supported by robust cash reserves and a growing pipeline.
RenovoRx Slides: Investor presentation
RenovoRx has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
MOUNTAIN VIEW, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
MOUNTAIN VIEW, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and comm...
RenovoRx announces FDA Orphan Drug Designation for oxaliplatin
RenovoRx (RNXT) announced that the FDA recently granted RenovoRx Orphan Drug Designation of oxaliplatin for the treatment of pancreatic cancer. The designation was issued by the FDA’s Office of Orphan...
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and Provides Seven Years of Market Exclusivity Third FDA Orphan Drug Designation Continues to Advance Re...
RenovoRx announces pharmacokinetic data using TAMP platform
RenovoRx (RNXT) announced that an abstract from a pharmacokinetic and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial has been published online in connection with the 2026 ...
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic ...
RenovoRx Transcript: A.G.P.'s Annual Virtual Healthcare Conference
TAMP technology enables targeted chemotherapy with reduced toxicity, driving strong revenue growth from the RenovoCath device. The pivotal TIGeR-PaC trial is nearing full enrollment, with final data expected in 2027. Ample cash reserves support ongoing commercial and clinical expansion.
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and comme...
RenovoRx reports Q1 adjusted EPS (8c), consensus (8c)
Reports Q1 revenue $563,000, consensus $463,250.
RenovoRx sees FY26 revenue $3M-$4M, consensus $3.24M
The company believes its current cash resources are sufficient to fund operations into at least the second half of 2027.
RenovoRx Earnings Call Transcript: Q1 2026
Record Q1 2026 revenue grew 136% sequentially, driven by rapid expansion to 16 active cancer centers and strong repeat orders. Guidance for 2026 revenue remains $3–$4 million, with a robust pipeline and sufficient cash to fund operations into 2027.
RenovoRx Earnings release: Q1 2026
RenovoRx released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
RenovoRx Quarterly report: Q1 2026
RenovoRx has published its Q1 2026 quarterly earnings report on May 14, 2026.
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP™ Thera...
RenovoRx Slides: Investor presentation
RenovoRx has posted slides in relation to its latest quarterly earnings report, which was published on May 4, 2026.
RenovoRx Proxy statement: Proxy filing
RenovoRx filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and com...